UBS sees 60% more upside in Shaily Engineering after a massive 700% rally in two years
Global brokerage UBS has initiated coverage on Shaily Engineering Plastics, India’s leading exporter of high-precision engineered plastic components, with a ‘Buy’ rating and a target price of ₹4,000, indicating a potential upside of 60% from the current market price. UBS highlighted Shaily’s unique patented technology for fixed-dose and auto-injector pens, positioning it strongly for the upcoming launch of generic GLP-1 therapies. With the GLP-1 (semaglutide) patent expiring in 2026 across India, Canada, and Brazil, UBS estimates a combined market of 550–600 million devices, translating to ₹80–85 billion in revenue by 2030.
Shaily has already secured 23–24 clients for the GLP-1 launch, supporting UBS’s projection of a 96% revenue CAGR for its healthcare segment between FY25–28. High en...








